Category: spasticity

Survey: Nearly One Out Of Six MS Patients Use Cannabis Therapeutically

One-quarter of patients with multiple sclerosis report having used cannabis therapeutically and nearly one out of six (16 percent) currently use it to treat symptoms of the disease, according to survey data commissioned by the North American Research Committee on MS. Those with more advanced symptoms of MS were more likely to report using cannabis therapeutically.

Study: Hemp Seed Oil Associated With Improved Clinical and Immunological Parameters In Multiple Sclerosis Patients

The consumption of legal hemp seed nutritional oil, in conjunction with the intake of evening primrose oils and a restrictive diet high in Hot-natured foods (such as pepper) and low in saturated fats and sugars, is associated with “significant improvement” in symptom management and immunological characteristics in subjects with multiple sclerosis, according to clinical trial data published this month in the scientific journal BioImpacts.

2012: The Year In Review — NORML’s Top 10 Events That Shaped Marijuana Policy

#1 Colorado and Washington Vote To Legalize Marijuana Voters in Colorado and Washington made history by approving ballot measures allowing for the personal possession and consumption of cannabis by adults. Washington’s law, which removes criminal penalties for the possession of up to one ounce of cannabis for personal use (as well as the possession of up to 16 ounces of marijuana-infused product in solid form, and 72 ounces of marijuana-infused product in liquid form), took effect on December 6. Colorado’s law, which allows for the legal possession of up to […]

Study: Cannabis Extracts Mitigate Muscle Stiffness In Multiple Sclerosis Patients

[Editor’s note: This post is excerpted from this week’s forthcoming NORML weekly media advisory. To have NORML’s news alerts and legislative advisories delivered straight to your in-box, sign up here.] The oral administration of cannabis extracts significantly reduces muscle stiffness in patients with multiple sclerosis (MS), according to just published clinical trial data published in the Journal of Neurology, Neurosurgery & Psychiatry. Investigators at the University of Plymouth, Clinical Neurology Research Group, in the United Kingdom assessed the use of cannabinoids versus placebo in 279 subjects with MS over a […]